Inventory 2012
Difficulty in research and development of new drugs，Difficult to go to Qingtian。This is a difficult period for the bitter water of the drug research and development industry，It is also the best time to be aggressive。
Astrikang announced earlier this year&D business further reorganization，Including the establishment of a new & ldquo; virtual & rdquo; neuroscience & ldquo; innovative drug unit & rdquo;，Johnson & Johnson Plan in California、Boston、London and China open 4 innovation centers，The purpose is to speed up the early innovation of new drugs & hellip; & hellip; These are just a microcosm of the R & D and transformation of multinational giants。
More and more old -fashioned large pharmaceutical companies have realized，In the past, the major research and development model industry has been out of date，The strategy party of more time and cost -effectiveness is wise for switching.。On the other hand，Domestic young innovative enterprises are moving the new drug selection in the same way，Take the opportunity to catch the lost stick in the hands of the giant。When the whistle of the open R & D competition sounds，We see the various colors of pharmaceutical companies & ldquo; Facial spectrum & rdquo;。
Foreign Chapter
Pfizer: Emphasize externalization strategy
At the Global UBS Life Science Conference on September 20 this year，Mikaeldolten, President of Pfizer Global Research and Development: & LDQUO; We start to pay attention to some core areas，Focus on emphasizing externalization strategies，Among them, choose the future CRO partner to establish alliances，At the same time, it will also acquire and cooperate with other biotechnology，Create a truly powerful cooperation network with the academic world。& rdquo;
Another，According to DOLSEN in its recent speech，Pfizer has terminated about 90 concept verification stages.。Pfizer's current research field is preferred in immunology and inflammation、Tumor、Cardiovascular disease、metabolism and endocrine diseases、Neuroscience and Pain、Vaccine and other major areas，Research on small molecules and macromolecular drugs。In addition to reducing the key areas of the disease，Pfizer is still adjusting and reduced its R&D activity，Pack some functions。For CRO，Pfizer selected 2 (icon and Parexel) as a strategic partner of the clinical trial from the original 17 functional service providers。
Starting in 2010，Pfizer established the Treatment Innovation Center (CTI)，This center is an open innovative cooperation mode，in order to get involved in the field of science Stake Sports Bettingstake online sports bettingand put biological treatment methods (antibodies、polypeptide and protein) and other treatment areas such as all therapy are transformed into clinical applications。
[Comments]
Lipur has since pushed to the market in 1998，It has always been Pfizer's main revenue source。Pfizer cannot generate a reserve army in time if it cannot generate & ldquo;，It will be difficult to continue glory。But，in torcetrapib、Dimebon and other series of key candidate drugs after the failure of advanced clinical trials，Pfizer has to seek support from external laboratories，So，Targeted acquisition and cooperation，To obtain the joint development of new drugs may be available，Become one of the most important strategies for Pfizer to respond to patented cliffs。
GlaxoSmot: Independent Innovation Unit
As a new R&part of D mode，GlaxoSmith's Drug Innovation Unit (DPUS) has its own independent budget and a three -year time window to complete a specific task，Among them, the opportunity to cooperate with external organizations。As of 2011，The progress of all 38 DPUS was evaluated by the Grammomosk's investment committee，This committee includes R&D senior managers、Business operation and external experts。In the 2011 evaluation，Create 4 new DPUS，Close the other 3。In the remaining DPUS，6 increase investment，5 reduces investment。Based on this evaluation，Grandulsk thinks，30 new medicines in the next 3 years，and enter the advanced development stage。
[Comments]
The previous organizational structure of Da Pharmaceutical Factory is highly concentrated，Manage more people from people with higher levels，Now they re -recognize，The team that invented the drug is the most important。2008，Grammomosk's history of unprecedentedly proposed to split the research center into DPUS，After that, every move and personnel composition of DPUS have become the most valuable intelligence in the eyes of competitors。This is R, which aims to dig in team potential&D new mode，It has also become the best interpretation of the people -oriented & rdquo;。Let's look at GlaxoSmith Kaish's passion for external alliances，Instead of saying that GlaxoSmithk is setting off a R&Revolution in business model，It is better to say that this is a strategic reshaping of the relationship between enterprises and its internal and external R & D participants。
Sanofi: practitioner of transforming medicine
Earlier this year，Sanofi signed a two -year agreement with Massachusetts General Hospital，The purpose of further promoting transformation of medical research，Then develop new new drugs for the treatment of vicious tumors and physical tumors for the treatment of blood systems。As of July this year，Sanofi passed its R&D platform develops 64 new molecular entities and vaccines，Among them, 29 new drugs (4 vaccines and 25 new molecular entities)，17 new drugs in stage II (3 vaccines and 14 new molecular entities)。
Emphasize the value of external partnership，Is Sinfei in recent years in R&D new features，One of the typical examples is the cooperation between Sanofi and Warpdrivebio。Warpdrivebio is created by the scientists of Harvard Medical College and the University of California and the risk investor of San Francisco，Specializing。In January 2012，Sanofi and the company announced the cooperation agreement，It will provide a startup funds of $ 125 million，But Warpdrivebio still stake online sports bettingstake betting appretains its strategic direction and business management mode，and fully have asset selection rights。
[Comments]
A firm follower and practitioner of transforming medicine，Sanofi always spares no effort to use medical value and transform medical guidance to the priority order of early investment portfolios，and actively integrate academic、Industry、Global high -quality resources in the clinical three realms，Clinical implementation of accelerated scientific research projects，Improve the output of new drugs。So far, the Sanofi R & D Center has been with 15 top domestic scientific research institutions、Hospital、Biological companies have established cooperative relationships，Among them includes the Shanghai Institute of Life Sciences, the Chinese Academy of Sciences、Shenyang Medicine University、Huaxi Hospital of Sichuan University、Peking University Oncology Hospital、Wuhan Union Hospital, etc.。When layout the global R & D framework，Sanofi once again positions China and Asia Pacific as North America、R & D Center compared to Europe，Silently confirming that R & D and emerging markets are still the only way for multinational giants to achieve new growth。
Novartis: There are everything in the R & D pipeline
Novartis invested 600 million U.S. dollars in Cambridge, Massachusetts, USA earlier this year，Used to establish a new laboratory and office，and for some R&D Unit and staff have reorganized。August，Novartis and the University of Pennsylvania, the University of Pennsylvania, establish research、Development and commercial partnership，Study on the main treatment of carcinogenic antigen receptor immunotherapy for cancer。In addition，The two parties will also establish a new R together&D center.
The current R & D of Novartis follows a new model of the so -called & ldquo; exploration and verification development & rdquo;。Explore development includes concept verification test，and involved small -scale clinical trials (usually 5 to 15 cases)，That is the content of the traditional stage I/II test。The purpose of these custom tests is to observe the safety of new drugs early、Effectiveness and toxicity。Once passed the concept verification test，This drug will enter a large -scale development stage，That is the traditional II/Ⅲ test，The purpose is to confirm the safety and effectiveness of the specified drug drug。otherwise，Traditional drug R&D mode will still be retained by Novartis.
[Comments]
See the data given from Novartis，139 clinical development projects are preparing，Another 73 new chemicals for a series of diseases。Its R & D team recently promised to give results to 13 advanced clinical projects，Provide 11 phase III clinical trial results in one year。Norhua's R & D investment last year was $ 9.58 billion，Drug research and development expenditure accounts for about 75%，The total number of development projects started to make it look at。
Norhua CEO Josephjimnez mentioned in a statement，& ldquo; Drugs at various R & D stages in the preparation guarantee that the continuous growth of future sales & rdquo;，The company is also expected to break the record of the annual revenue of 1 billion U.S.D.。Perhaps it is out of optimistic estimation of phase III clinical trials，Novartis has adopted a cautious and more conservative improvement of the existing R & D model。
Domestic chapter
Pioneer: eye -catching cooperation
September this year，Merhado Stake Sports Bettingstake online sports bettingand Xianyin Pharmaceuticals, stake betting appwhich was established in China, grabbed the eyeballs in China，In -depth cooperation between the two is interpreted as a new model of strong union，At the same time, it also shows the determination to strengthen the international cooperation strategy。Dested，The first human clinical trial cooperation project of Xianyin Pharmaceutical and the United States Apexigen & ldquo; APX003 (also known as BD0801) & rdquo;。APX003/BD0801 is the first therapeutic monoclonal antibody under the clinical trial，Currently developed by the pioneer and Apexigen in China。
The pioneer is committed to the creation of & ldquo;。This project planned to rely on the existing innovative drug research and development capabilities and platforms，Accept about 100 innovative drug research and development companies，Gathering 200 overseas biomedical leaders，It is intended to become & ldquo; Nanjing 321 Plan & rdquo; the main carrier of the biomedical industry and the leading domestic innovative drug entrepreneurial incubation base。
[Comments]
Knowing that domestic is not one step away from imitation to creation，Xianyin Pharmaceuticals laid the advantage in the field of innovative drugs as soon as possible，Out of the housekeeping skills & mdash; & mdash; integrate resources to the extreme。Whether it is investment to introduce early foreign projects，Still cooperate with the local government to build an incubation type entrepreneurial base，The purpose is to solve the funds that are currently plagued by local innovation at the lowest cost、Talent、Technology、Four factors of the project，At the same time provides industrial support for the acceleration of results，Make sure your new drug product line is not in time，Can be described as a win -win move。
Hengrui: aiming for tumor innovation medicine
April this year，Hengrui signed an investment cooperation agreement with the Chengdu High -tech Zone Management Committee，Increase of about 500 million yuan，Open the core & ldquo; Innovative drugs Chengdu production base & rdquo;，aiming for anti -tumor innovation drug research and development and production。Previous，Hengrui has successfully deployed Chengdu Shengdi Pharmaceutical Co., Ltd. in the high -tech zone，Mainly engaged in the follow -up research and development of innovative drugs。Innovative drugs Chengdu production base is completed，Hengrui said that it will continue to increase the investment in scientific research，Establish a western R & D base in Chengdu and increase cooperation with Sichuan medical institutions such as West China Hospital。
Heng Rui, which has always paid attention to the development of new drugs，The cumulative investment in research and development last year reached 420 million yuan，The proportion of total business income is nearly 9%。In the first half of this year，Hengrui Xin applied for 16 domestic patents and 8 global patents，There are 12 innovative drugs in the clinical research stage。
[Comments]
Heng Rui, who is determined to cultivate in the field of anti -tumor，I have a clear idea from the beginning。Strengthen the cooperation with academic institutions and hospitals，Not only to closely combine the industry -university -research，Complete the transition from basic research to clinical drugs，More importantly, using existing domestic platforms，Improve the scientific nature of the new drug research and development topic，Early providing clinical data for R & stake betting appD management decisions。and the high stake online sports betting-tech area of the new drug R & D resources，It has become the best choice of high -quality and high -quality promotion of project progress。
Green Leaf: Main new preparation
Green Leaf signed a cooperation agreement with the largest pharmaceutical company in South Korea in February this year，Obtaining hypoglycemic drug DPP-IV inhibitor DA-1229 develops in China、Exclusive authorization of production and sales，Immediately in June，Green Leaf ushered in the completion of the first phase of the group industrial park，Including drug preparations and interpretation technology laboratories、Long -acting slow -control interpretation and targeted technology development platforms including the test workshop and other series of supporting facilities in the micro -ball preparation workshop can be fully improved。
At present, there are nearly 10 varieties under the Green Leaf Group's micro -ball platform，Covering the spirit、Neurotrophic drugs and other treatment areas，Where，Long -acting slowly relieved micro -ball preparations for the treatment of Parkinson's disease LY03003 was approved by FDA and SFDA in January and April this year to enter the phase I clinical research。
[Comments]
It is not difficult to see，Green Leaf's main attack is the innovative preparation.，Therefore, it is inevitable to invest a lot of manpower and material resources，It is said that Green Leaf will take more than 10%of the sales income for high -level new drug research and development，Adhere to the company's intention and attachment to the self -forming key technology platform。The biggest difference between innovative preparation and innovative drugs，In the former, the former requires higher technical equipment for testing and large -scale production，Otherwise, the new preparation technology cannot be enlarged。High threshold、Low risk、Short R & D cycle and other features，Created the opportunity to cut into drug innovation for young green leaves，Under the background of the global competitive integration，Internationalized new drugs with independent intellectual property rights，It means that the capital and admission vouchers that have won the global market。
